Alluvi, known as BI 4744, presents a promising advance in obesity care. This dual activator targeting both GLP-1 and GIP receptors demonstrates remarkable efficacy in research trials, possibly surpassing available https://alluvi-healthcare098444.robobloggo.com/profile